retatrutide dosing in clinical trials ESC 2024: improves lipid and cardiovascular risk profile Phase II trial retatrutide dosing clinical trial retatrutide

Regarding fibrosis, while direct anti-fibrotic mechanisms are less established, preclinical studies indicate that GLP-1 RAs could suppress fibrogenic cell activation and reduce expression of pro-fibrotic genes encoding extracellular matrix proteins, potentially facilitating fibrosis regression in conjunction with improvements in steatosis and inflammation [29-32]

There is currently no established maximum duration for retatrutide use, as the drug is still in clinical development

In addition, compounded medications are typically not covered by insurance. Mir Ali, MD, a board-certified general surgeon, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, told MNT that while it is usually not harmful to microdose GLP-1 medications, they may be less effective

C.Olde DaminkS